Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291607 | 0.87 | FOLH1 (0.54) | L3MBTL1TDP1TP53SMN1; SMN2FOLH1 | |
| SCHEMBL5333596 | 0.84 | USP2 (0.61) | USP2TP53NPC1RAB9AABCB1 | |
| SCHEMBL7778557 | 0.81 | L3MBTL1 (0.53) | L3MBTL1TDP1USP2TP53NPC1 | |
| SCHEMBL31406503 | 0.80 | ALDH1A1 (0.64) | L3MBTL1TDP1USP2TP53NPC1 | |
| SCHEMBL2839519 | 0.80 | TSHR (0.66) | TDP1USP2TP53NPC1RAB9A | |
| SCHEMBL8677245 | 0.80 | ABCB1 (0.64) | USP2TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7346161 | 0.79 | L3MBTL1 (0.58) | L3MBTL1TDP1USP2TP53ABCB1 | |
| SCHEMBL7347241 | 0.79 | L3MBTL1 (0.51) | L3MBTL1TDP1USP2TP53NPC1 | |
| SCHEMBL27615709 | 0.78 | TDP1 (0.77) | L3MBTL1TDP1NPC1RAB9AABCB1 | |
| SCHEMBL8338571 | 0.78 | TDP1 (0.77) | L3MBTL1TDP1NPC1RAB9AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279248-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2024-08-22 | — | — | US | disclosed |
| EP-1485707-A4 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1583972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050042771-A1 | Identifying non-drug targets; use in drug design for improving knowledge of drug-target and drug-non-target interactions, so that drug adverse reactions can be reduced or eliminated in drugs such as troglitazone, rosiglitazone, pioglitazone, methotrexate, atorvastatin, celecoxib, rofecoxib, cerivastatin | CAPROTEC BIOANALYTICS GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1485707-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004064972-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004064972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003092581-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003092581-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030119021-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | L3MBTL1 4215/4885TDP1 2134/4885USP2 3593/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | L3MBTL1 1938/4885TDP1 1964/4885USP2 3874/4885 |
| US-20240279248-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | ADH5, ADH1A, ADH7 | L3MBTL1 3431/4885TDP1 1727/4885USP2 3717/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | L3MBTL1 1434/4885TDP1 2014/4885USP2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.